Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic Individuals

Dorota S Temple, Meghan Hegarty-Craver, Robert D Furberg, Edward A Preble, Emma Bergstrom, Zoe Gardener, Pete Dayananda, Lydia Taylor, Nana-Marie Lemm, Loukas Papargyris, Micah T McClain, Bradly P Nicholson, Aleah Bowie, Maria Miggs, Elizabeth Petzold, Christopher W Woods, Christopher Chiu, Kristin H Gilchrist, Dorota S Temple, Meghan Hegarty-Craver, Robert D Furberg, Edward A Preble, Emma Bergstrom, Zoe Gardener, Pete Dayananda, Lydia Taylor, Nana-Marie Lemm, Loukas Papargyris, Micah T McClain, Bradly P Nicholson, Aleah Bowie, Maria Miggs, Elizabeth Petzold, Christopher W Woods, Christopher Chiu, Kristin H Gilchrist

Abstract

Background: The COVID-19 pandemic highlighted the need for early detection of viral infections in symptomatic and asymptomatic individuals to allow for timely clinical management and public health interventions.

Methods: Twenty healthy adults were challenged with an influenza A (H3N2) virus and prospectively monitored from 7 days before through 10 days after inoculation, using wearable electrocardiogram and physical activity sensors. This framework allowed for responses to be accurately referenced to the infection event. For each participant, we trained a semisupervised multivariable anomaly detection model on data acquired before inoculation and used it to classify the postinoculation dataset.

Results: Inoculation with this challenge virus was well-tolerated with an infection rate of 85%. With the model classification threshold set so that no alarms were recorded in the 170 healthy days recorded, the algorithm correctly identified 16 of 17 (94%) positive presymptomatic and asymptomatic individuals, on average 58 hours postinoculation and 23 hours before the symptom onset.

Conclusions: The data processing and modeling methodology show promise for the early detection of respiratory illness. The detection algorithm is compatible with data collected from smartwatches using optical techniques but needs to be validated in large heterogeneous cohorts in normal living conditions. Clinical Trials Registration. NCT04204493.

Keywords: COVID-19; ECG; heart rate monitoring; heart rate variability; influenza; viral respiratory infection; wearable sensors.

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Mean daily total symptom score for symptomatic, asymptomatic, and uninfected individuals. Day 0 is the day of inoculation. Error bars represent standard deviation.
Figure 2.
Figure 2.
Acquired data plotted as functions of time for a symptomatic participant FC001; t = 0 marks the timing of the inoculation. (A) Interbeat interval (IBI) averaged in 5-minute epochs; (B) total symptom score (TSS); (C) activity averaged in 5-minute epochs and timing of sleep (S), acceleration due to gravity (g); and (D) z-score for IBI, matched for activity.
Figure 3.
Figure 3.
Standardized values of IBI and selected HRV metrics: (left) positive symptomatic participant FC001; (center) positive asymptomatic participant FC007; (right) participant FC002 who tested negative for the H3N2 virus. Abbreviations: TSS, total symptom score; z-HF, z-score high frequency; z-IBI, z-score interbeat interval; z-LF, z-score low frequency.
Figure 4.
Figure 4.
Twenty-four–hour mean values of z-scores for interbeat interval (z-IBI), low frequency (z-LF), high frequency (z-HF), and z-LF/HF ratio averaged across all H3N2-positive subjects in the study. Error bars indicate standard error of the mean.
Figure 5.
Figure 5.
Examples of Hotelling T2 statistic plotted as a function of time for symptomatic (FC001) and asymptomatic (FC007) positive participants, and for a negative (FC002) participant. Abbreviation: CL, control limit.
Figure 6.
Figure 6.
Timing of alerts (triangles) relative to symptom onset for all study participants using a threshold of 15.

References

    1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med 2019; 25:44–56.
    1. Li X, Dunn J, Salins D, et al. Digital health: tracking physiomes and activity using wearable biosensors reveals useful health-related information. PLoS Biol 2017; 15:e2001402.
    1. Clifton L, Clifton DA, Pimentel MA, Watkinson PJ, Tarassenko L. Predictive monitoring of mobile patients by combining clinical observations with data from wearable sensors. IEEE J Biomed Health Inform 2014; 18:722–30.
    1. Bayo-Monton JL, Martinez-Millana A, Han W, Fernandez-Llatas C, Sun Y, Traver V. Wearable sensors integrated with internet of things for advancing eHealth care. Sensors (Basel) 2018; 18:1851.
    1. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019; 381:1909–17.
    1. Radin JM, Wineinger NE, Topol EJ, Steinhubl SR. Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study. Lancet Digit 2020; 2:e85–93.
    1. Quer G, Radin JM, Gadaleta M, et al. Wearable sensor data and self-reported symptoms for COVID-19 detection. Nat Med 2020; 27:73–7.
    1. Zhu G, Li J, Meng Z, et al. Learning from large-scale wearable device data for predicting epidemics trend of COVID-19. Discrete Dyn Nat Soc 2020; 1–8.
    1. Mishra T, Wang M, Metwally AA, et al. Pre-symptomatic detection of COVID-19 from smartwatch data. Nat Biomed Eng 2020; 4:1208–20.
    1. Seshadri DR, Davies EV, Harlow ER, et al. Wearable sensors for COVID-19: a call to action to harness our digital infrastructure for remote patient monitoring and virtual assessments. Front Digit Health 2020; 2: 11.
    1. Miller DJ, Capodilupo JV, Lastella M, et al. Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. PLoS One 2020; 15:e0243693.
    1. Poongodi M, Hamdi M, Malviya M, et al. Diagnosis and combating COVID-19 using wearable Oura smart ring with deep learning methods. Pers Ubiquitous Comput 2021; 1–11.
    1. Hirten RP, Danieletto M, Tomalin L, et al. Use of physiological data from a wearable device to identify SARS-CoV-2 infection and symptoms and predict COVID-19 diagnosis: observational study. J Med Internet Res 2021; 23:e26107.
    1. Natarajan A, Su HW, Heneghan C. Assessment of physiological signs associated with COVID-19 measured using wearable devices. NPJ Digit Med 2020; 3:156.
    1. Shapiro A, Marinsek N, Clay I, et al. Characterizing COVID-19 and influenza illnesses in the real world via person-generated health data. Patterns 2021; 2:100188.
    1. Woods CW, McClain MT, Chen M, et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One 2013; 8:e52198.
    1. McClain MT, Constantine FJ, Nicholson BP, et al. A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study. Lancet Infect Dis 2021; 21:396–404.
    1. Sherman AC, Mehta A, Dickert NW, Anderson EJ, Rouphael N. The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology. Front Cell Infect Microbiol 2019; 9:107.
    1. Habibi MS, Chiu C. Controlled human infection with RSV: the opportunities of experimental challenge. Vaccine 2017; 35:489–95.
    1. Ramasamy S, Balan A. Wearable sensors for ECG measurement: a review. Sensor Rev 2018; 38:412–9.
    1. Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart rate sensors. NPJ Digit Med 2020; 3:18.
    1. Yuda E, Shibata M, Ogata Y, et al. Pulse rate variability: a new biomarker, not a surrogate for heart rate variability. J Physiol Anthropol 2020; 39:21.
    1. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions: I. The common cold as a clinical entity. AMA Arch Intern Med 1958; 101:267–78.
    1. Gwaltney JMJ, Colonno RJ, Hamparian VV, Turner RB. Rhinovirus. In: Schmidt NJ, Emmons RW, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 6th ed. Washington DC: American Public Health Association, 1989:579–614.
    1. Bittium . Bittium Faros technical specifications. Medical Technologies – Bittium Faros. . 2019. Accessed 1 July 2021.
    1. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043–65.
    1. Kubios . HRV analysis methods. . Accessed 1 July 2021.
    1. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol Heart Circ Physiol 1985; 248:H151–3.
    1. Champseix R. Aura-healthcare/HRV-analysis. . Accessed 1 March 2022.
    1. Kourti T, MacGregor JF. Process analysis, monitoring and diagnosis, using multivariate projection methods. Chemom and Intell Lab Syst 1995; 28:3–21.
    1. Kano M, Hasebe S, Hashimoto I, Ohno H. A new multivariate statistical process monitoring method using principal component analysis. Comput Chem Eng 2001; 25:1103–13.
    1. SAS . SAS/QC 14.2 user’s guide. . 2016. Accessed 1 July 2021.
    1. Zweig M, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561–77.
    1. Quer G, Gouda P, Galarnyk M, Topol EJ, Steinhubl SR. Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: retrospective, longitudinal cohort study of 92,457 adults. PLoS One 2020; 15:e0227709.
    1. Yien H-W, Hseu S-S, Lee LC, et al. Spectral analysis of systemic arterial pressure and heart rate signals as a prognostic tool for the prediction of patient outcome in the intensive care unit. Crit Care Med 1997; 25:258–66.
    1. Piepoli M, Garrard CS, Kontoyannis DA, Bernardi L. Autonomic control of the heart and peripheral vessels in human septic shock. Intensive Care Med 1995; 21:112–9.
    1. Muthuri SG, Venkatesan S, Myles PR, et al. Impact of neuraminidase inhibitors on influenza A (H1N1) pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses 2016; 10:192–204.
    1. Koonin LM, Patel A. Timely antiviral administration during an influenza pandemic: key components. Am J Public Health 2018; 108:S215–20.
    1. Moreno G, Rodríguez A, Sole-Violán J, et al. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Res 2021; 7.
    1. Atkins CY, Patel A, Taylor TH, et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis 2011; 17:1591.
    1. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204–14.
    1. Du Z, Nugent C, Galvani AP, Krug RM, Meyers LA. Modeling mitigation of influenza epidemics by baloxavir. Nat Commun 2020; 11:1–6.
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Eng J Med 2022; 386:1397–408.
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Eng J Med 2022; 386, 509–20.
    1. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Eng J Med 2022; 386:305–15.
    1. Kucharski AJ, Klepac P, Conlan AJK, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infect Dis 2020; 20:1151–60.

Source: PubMed

3
订阅